2.4 Eligibility criteria
We included randomised controlled trials (RCTs), non-randomised controlled trials and observational studies that assessed an intervention aimed at reducing or ceasing the prescription or use of a gabapentinoid in adults (≥18 years) for any indication (including off-label use) in a clinical setting. The comparator could be usual care (i.e. no intervention), placebo or an active control. Studies targeting deprescribing in the context of polypharmacy interventions (most commonly defined as ≥5 regular prescribed medications) were included if they reported gabapentinoid-specific data. The deprescribing intervention could be aimed at either the clinician, patient or both across any setting. Non-randomised trials were defined as trials where the allocation was not at random (e.g. quasi-randomised controlled trials). We excluded animal studies, non-interventional studies (e.g. commentaries) and those involving paediatric populations (<18 years) or patients living with cancer.